Notice of General Meeting
Released
Released
Announcement PDF
NOTICE OF
GENERAL MEETING
called at the request of shareholders under section 249D of
the Corporations Act 2001 (Cth)
Including Explanatory Notes
and Proxy Form
The Directors of Percheron Therapeutics Limited UNANIMOUSLY
recommend that Shareholders vote all Shares they hold AGAINST all
resolutions. Directors do not consider the resolutions to be in the best
interests of the Company or its Shareholders.
To be held:
9:00 am (Queensland time) time on Tuesday, 4 March 2025
Minter Ellison, One Eagle – Waterfront, Level 22
1 Eagle Street Brisbane, Queensland
-andVirtually at this web address - https://meetings.lumiconnect.com/300-679-977-956
Meeting ID: 300-679-977-956
This is an important document. It should be read in its entirety.
If you are in doubt as to the course you should follow, consult your financial or other professional adviser.
If you have any questions about the General Meeting or the Resolutions to be voted on please call the
Company Secretary, Ms Deborah Ambrosini on +61 411 828 748.
Statement by the Directors of
Percheron Therapeutics Limited
Issued in response to the call for a General Meeting of the
Members of the Company by David Kenley, entities associated
with Gennadi Koutchin, Robert Moses, Gregory Peters, and
Dale Reed, and their respective related parties
24 January 2025
Contents
Page 2 of 40
1. Introduction
Dear Shareholder,
As you will see from the accompanying documents, five of the Company’s
shareholders, acting either individually or through their associated entities,
representing just over 5% of the issued share capital, have called for a General
Meeting of the Company’s members. They seek to remove two of the three
existing Directors, Dr Charmaine Gittleson and Dr James Garner, and to install
two replacement Directors, Mr Gennadi Koutchin and Mr Gregory Peters.
It is unfortunate that the Mr Kenley, Mr Koutchin, Mr Moses, Mr Peters, and
Mr Reed did not approach the Directors before submitting their call for a
General Meeting. Had they done so, and had they given us a reasonable
opportunity to try and find common ground in respect of their concerns, we
would have sought at all costs to avoid the enormous distraction and cost of
this process.
The requisitioning shareholders have provided a statement as to their rationale
for the meeting and have outlined the credentials of Mr Koutchin and Mr
Peters as putative Directors of the Company, and this is included with the
Notice of Meeting. We urge you to read it carefully.
In the meantime, the Board provides here its own statement. We outline the
progress that the Company has made over the relatively short period that we
have been in office. We describe our strategy to restore the Company following
the failure of the ATL1102 phase IIb trial in December 2024. And we respond to
some of the points raised by Mr Koutchin and Mr Peters.
Dr Gil Price has indicated that he would not remain on the Board if the motions
to remove Dr Gittleson and Dr Garner are successful. As such, we offer this
statement on behalf of the entire Board. We have worked together as a team
to bring Percheron this far, and we will respond to this challenge in the same
way.
We understand that the negative outcome of the phase IIb trial is deeply
disappointing for all who have been involved in the Company. We can assure
you that the regret we feel as Directors is absolutely no less profound than that
felt by our shareholders.
However, it is important to be clear that the trial did not fail as a result of any
action or inaction by the Board, or the management team, or the third-party
vendors who conducted the trial. The trial failed because ATL1102 was not, in
the end, able to prove itself an effective therapy for Duchenne muscular
dystrophy. That is, unfortunately, a possible outcome every time a company
starts a clinical trial, and it is in fact the most common outcome in drug
development. Indeed, this is the reason regulatory agencies rightly demand, on
behalf of society, that we conduct robust clinical studies – so that patients can
be sure of receiving only those medicines that are battle-tested in the
demanding environment of a randomised-controlled trial.
Page 3 of 40
What matters now is how we are able to right the Company and to create
within it a new path forward to generate shareholder value. We have a clear
plan to do that, and each of us has the experience of having done so before.
We had begun to turnaround the challenged business that was Antisense
Therapeutics, and we are well-equipped to continue that transformation.
Mr Koutchin and Mr Peters do not appear to have such a plan, nor do they
have all the scientific and medical expertise necessary to assess biotech assets
in order to develop such a plan, nor do they have experience in running a
publicly listed life sciences company. We believe that their appointment to the
Board would be profoundly against the interests of the Company and its
shareholders, and we recommend that you vote AGAINST all resolutions put
forward at this meeting. Every vote is important, we encourage every
shareholder to exercise their right to determine the Company’s future
leadership.
Should you grant us the opportunity to continue as a Board, we can assure you
that our single-minded focus will be on rebuilding Percheron, so that it can
become the first-class drug development Company each of us joined the Board
to create, so that we can recoup and grow, to the fullest extent possible, the
value of your investments, and so that we can all move forward from this
setback as swiftly and effectively as we can. We have already been working to
these goals, and we will be resolute in continuing to do so for as long as we
remain Directors of the Company.
Yours faithfully,
Dr Charmaine Gittleson
Chair of the Board
Dr Gil Price
Non-Executive Director
& Chair of Audit
Dr James Garner
Managing Director
Page 4 of 40
2. Background to the Company
For the benefit of shareholders who may be new to the Company, the Directors
offer the following remarks by way of historical orientation.
Percheron Therapeutics Limited (formally Antisense Therapeutics Limited) was
incorporated in November 2000 and was listed on the Australian Securities
Exchange in December 2001. It remains one of the oldest biotechnology
companies listed on the ASX.
Since its inception, the Company has focused on the development of novel
therapeutics for human use. The Company’s entire pipeline to date –
comprising three drugs code-named ATL1101, ATL1102, and ATL1103 – was
developed through a partnership with Ionis Pharmaceuticals (NASDAQ:IONS),
based in Carlsbad, CA.
Despite the theoretical promise of each of these assets, progress was slow
during the first two decades of the Company’s existence. ATL1101, a potential
prostate cancer therapy, appears to have been abandoned by the Company
around 2013. ATL1102 completed a phase II study in multiple sclerosis in 20091.
The asset was licensed to Teva Pharmaceuticals (NYSE: TEVA), but the license
was terminated and the asset handed back2. ATL1103 completed a phase II
study in acromegaly around 20143. It was also licensed, to Strongbridge
Biopharma plc, but that license was also handed back. The Company does not
appear to have undertaken further development of the ATL1103 asset
thereafter.
In around 2015, the Company pivoted the ATL1102 program to development in
Duchenne muscular dystrophy (DMD). The rationale for doing so was some
newly published research by Pinto-Mariz et al. which showed that CD49d, the
target of ATL1102, was a potential target, and disease progression biomarker,
for immunotherapy in DMD4. The drug successfully completed a phase IIa pilot
study in DMD in 2020 with encouraging results5. However, the Company’s
failure to complete a nine-month toxicology study, as required by FDA, meant
that no further clinical work was undertaken for some years.
Meanwhile, many of the key activities required in drug development were
neglected. Early-phase studies to establish appropriate dosing were not
performed. No clinical study report (CSR) for the phase IIa study was produced
within a reasonable time period. This critical document captures all the results
of the study, provides full detail as to the methods and design, undergoes
stringent quality assurance, and is ultimately shared with investigators and
regulatory agencies. Publication of the data in a peer-reviewed scientific
journal was delayed. Safety data from all clinical programs conducted by the
Company was not appropriately collated and required filings to FDA were not
made.
1 V Limmroth et al. (2014) Neurology 83 (20) 1780-1788
2 ANP announcement to ASX of 24 March 2010
3 PJ Trainer et al. (2018) Eur J Endocrinol. 179 (2) 97–108
4 F Pinto- Mariz et al. (2015) Skeletal Muscle 5 (45)
5 IR Woodcock et al. (2024) PLoS ONE 19 (1)
Page 5 of 40
Perhaps in recognition of the fact that a Board composed entirely of business
people and scientists was not sufficient for the Company’s needs, the Board
appointed two highly experienced drug developers as Directors. Dr Charmaine
Gittleson joined the Board in March 20216 and Dr Gil Price in October 20217.
The legacy Directors retired over following months, and Dr Gittleson became
Chair of the Board in November 20218.
Dr Gittleson and Dr Price inherited a company with some potentially strong
scientific underpinnings, but with a pipeline that had spent over twenty years
in development with little to show and, consequently, a weariness toward the
Company’s story among professional investors.
At the time, to the extent that the Company had a strategy for ATL1102, it was
to develop it for the European market, a challenging approach even for a
European company. In general, the Company did not possess all the necessary
experience and expertise within the management team to progress the asset,
and had relatively neglected the critical US market.
During 2022, the new Directors refocused the Company around ATL1102 in
DMD, given the encouraging results seen in the completed phase IIa study.
They designed and implemented a phase IIb study to confirm the drug’s
efficacy in this disease. They initiated a nine-month toxicology study to rectify
deficiencies repeatedly identified by the United States Food & Drug
Administration (FDA)9. And they raised capital to allow initiation of the planned
phase IIb study, which occurred in June 202310.
In August 2023, Dr James Garner joined the Company as CEO11. Dr Garner
recruited highly experienced executives in the United States and Australia. He
initiated an investor relations campaign which focused on repairing the
Company’s reputation among both institutional and retail investors. And he
embarked on an aggressive program of outreach to potential partners,
recognising that international commercialisation of ATL1102 would require the
resources of a larger company.
In December 2024, the Company reported initial data from the phase IIb study
of ATL1102, now known as avicursen12. Much to the disappointment of all
involved, the drug showed no convincing evidence of activity in this disease,
and the Board immediately made the difficult decision to abandon the ongoing
clinical trial.
6 ANP Announcement to ASX of 22 March 2021
7 ANP Announcement to ASX of 4 October 2021
8 ANP AGM Presentation of 15 December 2021
9 ANP Announcement to ASX of 14 March 2023
10 ANP Announcement to ASX of 8 June 2023
11 ANP Announcement to ASX of 7 August 2023
12 PER Announcement to ASX of 18 December 2024
Page 6 of 40
3. The Board’s Track Record at Percheron
The three current Directors of the Company, being Dr Gittleson, Dr Price, and
Dr Garner, have an average tenure on the Board of approximately three years.
Dr Gittleson was most recently re-elected to the Board in November 2023, and
Dr Price was re-elected in November 2024. During the period of their tenure,
they have made important progress in advancing the Company’s interests on
behalf of its shareholders.
3.1 Rectification of Significant Deficiencies with US FDA
At the time Dr Gittleson and Dr Price joined the Board, the ATL1102 program
had been on ‘partial clinical hold’ with the US FDA since at least August 201713,
meaning that the Company could only undertake clinical trials in the United
States under very limited conditions. The principal reason for this was the FDA’s
requirement for a nine-month toxicology study in non-human primates, a
routine requirement for drugs such as ATL1102 being developed in diseases
such as DMD. These requirements were made clear to the Company as early as
August 2017 and reiterated on several occasions thereafter.
Nine-month toxicology study
commenced in 2022 and
completed in 2024
Following the appointment of the new Board in 2021, the Company
commenced work on a nine-month GLP toxicology study in 2022. The study
began dosing in 2023 and was completed on schedule in 2024.
In the meantime, under the oversight of Dr Gittleson and Dr Price, the
Company repaired other procedural deficiencies in respect of its regulatory
obligations. For example, Data Safety Update Reports (DSURs) had not been
filed for at least five years, despite this being a Federal requirement under US
law. The Company has since been restored to full compliance in this and other
key respects.
3.2 Implementation of an International Phase IIb Clinical Trial for Avicursen
(ATL1102) in Duchenne Muscular Dystrophy
Under the previous Board, high-level plans had been developed for an
international phase III trial of ATL1102 in DMD. In September 2021, the
Company negotiated a Paediatric Investigational Plan (PIP) with the European
Medicines Agency (EMA)14. The PIP committed the Company to perform a large
phase III study in non-ambulant boys, as well as two further studies in
ambulant boys.
This plan would have required a large number of patients over a significant
period of time. The previous Board had internally costed the phase III study at
$10-15 million. Discussion with a contract research organisation on commercial
terms indicated a more plausible estimate of $70 million for the phase III study
alone. With the assistance of Mr Koutchin as a corporate advisor, the Company
13 ANP Announcement to ASX of 27 July 2017
14 ANP Announcement to ASX of 30 September 2021
Page 7 of 40
attempted to finance a phase III study but was unable to raise sufficient
funds15.
International phase IIb clinical
trial commenced in 2023
The new Directors took the view that it was neither feasible nor appropriate to
make such a substantial investment of shareholders’ funds on the basis of just
nine patients of data in the previous phase IIa study, especially in the absence
of extended toxicology data or conventional phase I dose escalation data. They
designed instead a focused phase IIb study, which was designed to validate the
earlier data as quickly and efficiently as possible, while retaining the possibility
of accelerated approval with supportive data. That study began
implementation in 2022 and, following recruitment of a new clinical team,
recruited its first patient in June 2023.
Under the leadership of Dr Garner, following his appointment as CEO in August
2023, the study was enhanced in several important respects. A fifth country
was added to accelerate recruitment16. Additional data collection was added to
the protocol to provide a broader and more qualitative evidence base in
support of the drug. And a post-trial access program was implemented at the
request of several investigators17.
Notwithstanding the disappointing outcome of this study, it is important to
recognise the quality of its execution. In particular, the study enrolled quickly.
Of the 65 industry-sponsored phase II and phase III DMD studies listed in
ClinicalTrials.gov, the average time to primary completion is 2.8 years. For the
Percheron study, it was 1.5 years, or nearly twice the speed of the industry
benchmark.
Shareholders may note the failure of this study and ask whether this reflects
poorly on its design. They should be assured that it does not, and that the
primary goal of clinical trials is, above all else, to provide a definitive answer. It
is a simple fact of the drug development business that the majority of drugs in
development will fail. If they are to do so, it is in the interests of all concerned
that their failure is determined as early and as definitively as possible. The
phase IIb study of ATL11102 was designed to provide clarity, and it did so.
3.3 Extensive Partnering Campaign for ATL1102
In late 2023 and throughout 2024, the Company conducted an extensive
outreach to potential licensees for ATL1102, as there had previously been
limited activity in this area. Company executives, including Dr Garner, attended
key international partnering conferences, such as the JP Morgan Healthcare
Conference and the BIO International Convention. A confidential data room
was established to permit effective due diligence by interested parties.
Company in contractual
negotiations with multinational
pharma partner at time of
study termination
In total, the Company engaged with more than 50 potential partners, and the
most advanced of these discussions resulted in an agreed non-binding term
sheet and the initiation of contractual negotiations with a multinational
pharmaceutical company during 2024. The Board had hoped to consummate
these negotiations shortly after receiving the clinical trial data in December
15 ANP Announcement to ASX of 1 November 2021
16 PER Announcement to ASX of 31 January 2024
17 PER Announcement to ASX of 21 October 2024
Page 8 of 40
2024. Unfortunately, as a result of the negative data, all such negotiations are
now suspended indefinitely.
3.4 Rehabilitation of the Company Among the Investment Community
By the time the new Board took office in 2021, and despite Mr Koutchin’s
efforts in investor relations, the Company was regarded with a degree of
weariness by the investment community, who noted slow progress in
advancing the Company’s pipeline.
The new Directors set about repairing the Company’s reputation among
professional investors through a simplified and more focused story and a
tighter emphasis on execution.
Four equity research analysts
covering Percheron at time of
trial cancellation
Following the appointment of Dr Garner as CEO in 2023, the Company began a
regular program of ‘Open House Meetings’, in which senior executives from the
Company met with shareholders in capital cities at six-monthly intervals. The
Company was invited to present at investor conferences, including in recent
months the HealthInvest Conference and the Pitt Street Research Life Sciences
Conference in September 2024, the Wilsons Drug & Device Conference in
October 2024, and the Bell Potter Healthcare Conference in November 2024. In
addition to the single equity research analyst who had been covering the stock
through 2022, two others resumed coverage in 2023, and a fourth initiated
coverage in 2024, providing the Company with the deepest level of research
interest it had enjoyed since its founding.
At the beginning of 2024, the Company changed its name from Antisense
Therapeutics to Percheron Therapeutics, following approval by shareholders at
the 2023 AGM18. The rebranding was supported by a new website, deeper
social media activity, and an extensive upgrade of the Company’s corporate
collateral and marketing materials.
3.5 Funding Completion of the Phase IIb Clinical Trial
The Company undertook capital raises in 2023 and 2024, raising $11.6 million
and $14.9 million respectively. Both transactions were performed at a discount,
as is almost universally the case for pre-revenue biotech companies. However,
neither transaction incurred option coverage, and both were supported by
well-regarded institutional investors.
The Board deliberately took the approach of performing several smaller
transactions to fund the Company to key milestones, rather than funding the
entire phase IIb trial in a single transaction, so as to minimise the dilution to
shareholders. The 2024 raise was consequently performed at a 60% premium
to the 2023 raise.
Substantial institutional
investment in Percheron
Through these successive financings, the Company was able to attract
significant institutional interest to the share register, including a substantial
holding by Platinum Asset Management, one of the most well-regarded sector-
18 PER Announcement to ASX of 2 January 2024
Page 9 of 40
specialist funds in Australia, and more than a dozen smaller positions by other
institutional holders.
On each occasion, and as a matter of fairness to existing holders, the Company
offered a Share Purchase Plan to existing shareholders, which ensured that
they had the ability to purchase stock on the same terms as the participants in
the placement.
3.6 Recruitment of an Experienced Executive Team
Biotech is perhaps among the most knowledge-intensive industries, and any
biotech company is therefore only as strong as the personnel who lead it and
propel it. The Board has focused over its tenure on building and retaining a
first-class team.
Highly experienced executives
appointed to management
team
The appointment of Dr Garner as CEO in August 2023 is perhaps the most
visible element of this. However, the Company has built an exceptionally strong
team of executives, with Deborah Ambrosini joining in June 2024 as Chief
Financial Officer19 and Dr Cathryn Clary as Chief Medical Advisor20. These
individuals are supported by a highly experienced operational team, several of
whom have joined from CSL Limited, having previously worked with Dr
Gittleson there.
It is not enough for a company simply to hire experienced employees – it must
also appropriately manage and incentivise them. Under the oversight of the
Remuneration Committee of the Board, the Company put in place a robust
performance management system, starting in FY2024. All employees are
allocated specific and challenging objectives for the fiscal year, and part of their
compensation is made dependent on the achievement of these objectives.
Such an approach is common in most successful companies but, to the
knowledge of the Directors, had not previously been utilised by Percheron
during its life as Antisense.
3.7 Expansion of the Board
The current Directors had recognised the value of enriching the Board and had,
in the fourth quarter of CY2024, identified a potential additional Director of the
Company. The candidate in question would have brought significant strategic,
commercial, and capital markets experience to the Company, along with deep
networks in Australia and the United States. The individual had already
undergone vetting, and the Board had hoped that they may have been
appointed in the first quarter of CY2025. As a result of the process initiated by
Mr Koutchin and Mr Peters, that process has been put on hold. Should the
current Directors remain in office, they will do everything possible to retain the
very highly credentialed candidate that was previously identified.
19 PER Announcement to ASX of 17 June 2024
20 PER Announcement to ASX of 3 June 2024
Page 10 of 40
3.8 Reduction in Operating Expenditure
Careful cost management has
allowed more Company funds
to be directed to R&D
The Board has focused on reducing the Company’s cost base over recent years.
Calculated on a cash basis, the Company spent significantly more on valuegenerating R&D, and substantially less on staff costs and general and
administrative expense, in FY2024 than it did in FY2021, before the current
Board’s appointment:
R&D
Staff Costs
G&A
FY2021
FY2024
(before current Board)
(with current Board)
59.0%
18.0%
22.9%
65.7%
15.7%
18.6%
* R&D = Research and Development; G&A = General and Administrative
By way of example, the Company has relocated its offices from the Toorak to a
serviced office in the Melbourne CBD, resulting in approximately a 50% saving
on occupancy cost. The Company has also terminated a number of consulting
and contractor agreements.
3.9 Renegotiation of Agreement with Ionis Pharmaceuticals
Relationship with Ionis placed
on more commercial footing
The original agreement with Ionis Pharmaceuticals was executed in 2001 and
revised in 2009. It described a research collaboration but was not appropriate
for a commercial product. In 2024, the new Board executed a revised
agreement which provided greater clarity regarding the treatment of ATL1102
and ATL1103 and which substantially facilitated partnering discussions.
3.10 Engagement with Clinicians, Academia, and Patient Advocacy
Company profile has been
greatly elevated with key
stakeholders
By virtue of each having worked in the rare diseases field, each of the Directors
are intimately aware that success in a disease such as Duchenne muscular
dystrophy requires extensive engagement with the clinician community, and
with patient advocacy.
Prior to the new Board taking office in 2021, the Company was largely
unknown to these key stakeholders. During their tenure, the current Board and
management have invested significant time in building relationships with
advocacy groups such as Parent Project Muscular Dystrophy, Cure Duchenne,
and the Muscular Dystrophy Association, as well as with their Australian peers.
Despite the failure of the ATL1102 phase IIb study, these relationships remain
potentially an asset of the Company and are, moreover, inextricably personal to
the Directors who have built them
Page 11 of 40
4. The Board’s Strategy to Rebuild the Company
The Board began to outline the key elements of its plans for the Company in its
letter to shareholders of 6 January 202521. The key points are recapitulated and
expanded upon here.
Trial failures are a common
challenge faced by biotech
companies
For context, it is important to reiterate that Percheron is not the first biotech
company to face such a situation. For example, in the weeks following
Percheron’s ATL1102 readout, Neumora Therapeutics (NASDAQ: NMRA)
announced a negative phase III result for their depression program, resulting in
an 80% drop in share price, and Sangamo Therapeutics (NASDAQ: SGMO) saw a
50% decline in value after Pfizer terminated a partnership for a gene therapy in
haemophilia. In 2023, Fibrogen (NASDAQ: FGEN), a company working primarily
in DMD, announced negative results from two trials of their investigational
product, pavrelumab. The company’s stock declined approximately 85% on
release of the results. Fibrogen successfully pivoted to three oncology
programs licensed in from Fortis Therapeutics, and has been slowly rebuilding
shareholder value since then.
Sadly, failure is a common event in drug development. The companies that
survive and flourish after a setback are those that have clear plans to move
forward, and which have the experience and expertise to refocus themselves.
For Percheron, the Board’s strategy consists for the time being in four pillars,
which are being pursued in parallel.
1. Understand the ATL1102 Trial Results
The Company has already begun a detailed examination of the trial results,
which will be informed by additional packages of data throughout January and
early February.
An analysis of the phase IIb
study is ongoing, and is
expected to conclude by end
of 1Q CY2025
The team is approaching these analyses in an algorithmic way: to understand
first whether there were any issues with the investigational product itself, then
to examine the execution of the study, and finally to consider scientific
questions as to its activity in DMD patients. These analyses to be completed by
the end of the first calendar quarter of 2025, and will be shared
comprehensively with all stakeholders as they are completed.
Another question which the team will try to address is why the results of the
randomised phase IIb trial differed from the earlier single-arm phase IIa study.
Sometimes, subtle differences in the patient population help to explain this,
but it is also sometimes the case that drugs simply perform less well in larger,
randomised trials than they do in small, earlier-stage exploratory trials, and this
is one of the primary reasons that regulatory agencies such as FDA typically
demand randomised data at some stage in a drug’s development.
21 PER Announcement to ASX of 6 January 2025
Page 12 of 40
2. Identify Value in the Company’s Existing Pipeline
Board will carefully review
other opportunities in current
pipeline
The Company has frequently noted that DMD is not the only potential use for
ATL1102, and data has been generated for the drug in diseases ranging from
autoimmune epilepsy to asthma. To refocus around one of these other
indications, the Board will need to satisfy itself that there is a high likelihood of
success, and that the negative result on the DMD study does not prejudice the
outcome in another indication. This will be a complex scientific evaluation, but
an important one, because the Company needs to ensure that it neither
abandons a valuable program prematurely, nor falls into the trap of ‘sending
good money after bad’.
3. Diversify the Portfolio
Percheron will likely need to
bring in one or more new
assets to the pipeline
During its ongoing strategic review of the Company, the Board had already
concluded that Percheron would need to acquire one or more new assets to
achieve a sustainable pipeline and had initiated activities to meet this objective
in 2024. Regardless of the conclusions that emerge from an analysis of the trial
and the current pipeline, the Board continues to consider diversification to be
imperative. The implicit risk associated with the existing assets would make the
Company a challenging investment proposition in the medium term if those
were the only programs in development. To be able to appeal to the broadest
possible range of investors, the Company will need to show that is not
dependent on a single technology platform, or on a single family of drug
candidates.
Each of the current Directors has significant exp
Share your feedback
Discover